Literature DB >> 30100690

Old and New Drug Classes Expanding To Include Glaucoma Treatments.

Troy Kish.   

Abstract

Poor patient adherence is fueling keen interest in the development of drugs for glaucoma management. Several long-acting formulations of existing medications are in the early stages of development, as are new therapeutic classes such as guanylate cyclase activators.

Entities:  

Year:  2018        PMID： 30100690      PMCID： PMC6065491     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  7 in total

1.  Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial.

Authors:  Richard A Lewis; William C Christie; Douglas G Day; E Randy Craven; Thomas Walters; Marina Bejanian; Susan S Lee; Margot L Goodkin; Jane Zhang; Scott M Whitcup; Michael R Robinson
Journal:  Am J Ophthalmol       Date:  2016-12-22       Impact factor: 5.258

Review 2.  Glaucoma.

Authors:  Jost B Jonas; Tin Aung; Rupert R Bourne; Alain M Bron; Robert Ritch; Songhomitra Panda-Jonas
Journal:  Lancet       Date:  2017-05-31       Impact factor: 79.321

3.  Barriers to adherence with glaucoma medications: a qualitative research study.

Authors:  J Lacey; H Cate; D C Broadway
Journal:  Eye (Lond)       Date:  2008-04-25       Impact factor: 3.775

4.  Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow.

Authors:  Jenny W Wang; David F Woodward; W Daniel Stamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-16       Impact factor: 4.799

5.  Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).

Authors:  Janet B Serle; L Jay Katz; Eugene McLaurin; Theresa Heah; Nancy Ramirez-Davis; Dale W Usner; Gary D Novack; Casey C Kopczynski
Journal:  Am J Ophthalmol       Date:  2017-12-01       Impact factor: 5.258

Review 6.  Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.

Authors:  Yih-Chung Tham; Xiang Li; Tien Y Wong; Harry A Quigley; Tin Aung; Ching-Yu Cheng
Journal:  Ophthalmology       Date:  2014-06-26       Impact factor: 12.079

Review 7.  Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis.

Authors:  Seth R Flaxman; Rupert R A Bourne; Serge Resnikoff; Peter Ackland; Tasanee Braithwaite; Maria V Cicinelli; Aditi Das; Jost B Jonas; Jill Keeffe; John H Kempen; Janet Leasher; Hans Limburg; Kovin Naidoo; Konrad Pesudovs; Alex Silvester; Gretchen A Stevens; Nina Tahhan; Tien Y Wong; Hugh R Taylor
Journal:  Lancet Glob Health       Date:  2017-10-11       Impact factor: 26.763
  7 in total
  3 in total

Review 1.  Adenosine receptors as promising targets for the management of ocular diseases.

Authors:  Eleonora Spinozzi; Cecilia Baldassarri; Laura Acquaticci; Fabio Del Bello; Mario Grifantini; Loredana Cappellacci; Petrelli Riccardo
Journal:  Med Chem Res       Date:  2021-01-25       Impact factor: 2.351

2.  Lowering the Intraocular Pressure in Rats and Rabbits by Cordyceps cicadae Extract and Its Active Compounds.

Authors:  Li-Ya Lee; Jui-Hsia Hsu; Hsin-I Fu; Chin-Chu Chen; Kwong-Chung Tung
Journal:  Molecules       Date:  2022-01-21       Impact factor: 4.411

Review 3.  RhoA-ROCK Signaling as a Therapeutic Target in Traumatic Brain Injury.

Authors:  Shalaka Mulherkar; Kimberley F Tolias
Journal:  Cells       Date:  2020-01-18       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.